Results 241 to 250 of about 68,732 (285)
Some of the next articles are maybe not open access.
Orphan Drugs: The Question of Products Liability
American Journal of Law & Medicine, 1985AbstractOrphan drugs, essential for die treatment of persons widi rare diseases, generally are unprofitable for manufacturers to develop and market. While congressional and administrative efforts to promote die development of orphan drugs have met widi modest success, application of products liability doctrine to orphan drug sponsors could subvert ...
openaire +2 more sources
Evaluation of Orphan Products by the U.S. Food and Drug Administration
International Journal of Technology Assessment in Health Care, 1992AbstractOrphan drug products generally are used in treating or preventing rare diseases. The small number of patients available for study may create special problems in the evaluation of these products. This paper examines some of the special problems that are associated with the design and implementation of studies to evaluate the safety and efficacy ...
M E, Haffner, J V, Kelsey
openaire +2 more sources
Orphan drugs and paediatric medicinal products
Pharmaceuticals Policy and Law, 2013While the safety and availability of medicinal products for the majority of adult patients has steadily improved in recent decades, for children and people suffering from rare diseases (orphan diseases) there is a lack of approved medicinal products for these patient populations.
openaire +2 more sources
2017
Over 30 years ago, the United States (US) Congress passed the Orphan Drug Act (ODA) to encourage the development of products for rare diseases or conditions ("orphan products"). The Act provided incentives to sponsors for developing products with orphan designation and established a grant program to fund studies of orphan products.
openaire +2 more sources
Over 30 years ago, the United States (US) Congress passed the Orphan Drug Act (ODA) to encourage the development of products for rare diseases or conditions ("orphan products"). The Act provided incentives to sponsors for developing products with orphan designation and established a grant program to fund studies of orphan products.
openaire +2 more sources
Labeling Pediatric Products: BPCA Efforts and Orphan Drug Opportunities
The Journal of Pediatric Pharmacology and TherapeuticsOBJECTIVE Although the Orphan Drug Act (ODA) has substantially increased the number of therapies available for rare diseases, there are still unmet needs for drug development in pediatric patients. The current study represents an exploratory collaborative effort from the National Institutes of Health (NIH) and the US Food and Drug Administration (FDA)
Hui Wei +3 more
openaire +1 more source
Survey Indicates 133 Orphan Drug Products in Development for 96 Relatively Rare Disorders
JAMA: The Journal of the American Medical Association, 1989ABSTRACT EIGHTY-FIVE companies have 133 drugs in various stages of development for 96 rare diseases.This is the first comprehensive listing of orphan drugs since the Orphan Drug Act became law in 1983. The list was compiled by the Pharmaceutical Manufacturers Association in response to a request by the National Commission on Orphan Diseases (JAMA. 1989;
openaire +1 more source
Clinical Pharmacology & Therapeutics, 2010
Many neurological diseases or conditions are rare disorders. The Orphan Drug Act (ODA) of 1983 was promulgated to promote the development of products for such conditions. In this Opinion piece, we discuss how the ODA has affected neurological diseases, note how current and future sponsors (any person(s) or entity (i.e., academic, corporate body ...
K A, Burke +3 more
openaire +2 more sources
Many neurological diseases or conditions are rare disorders. The Orphan Drug Act (ODA) of 1983 was promulgated to promote the development of products for such conditions. In this Opinion piece, we discuss how the ODA has affected neurological diseases, note how current and future sponsors (any person(s) or entity (i.e., academic, corporate body ...
K A, Burke +3 more
openaire +2 more sources
The Orphan Drug Act and the Federal Government's Orphan Products Development Program.
Public health reports (Washington, D.C. : 1974), 1984Through the combined efforts of agencies and organizations in the public and private sector, drugs have been made available that would not have been at hand without a specific focus on the orphan drug issue. It is anticipated that these cooperative efforts will continue beyond the first enthusiastic burst engendered by the inception of new and ...
openaire +1 more source
Orphan products: drugs and devices for rare diseases.
Nursing economic$, 1993The issues of orphan products include an inadequate definition of orphan status that hampers implementation of the legislation, difficulties in evaluating the products themselves in order to ensure safety and effectiveness, neglect in developing orphan devices, and conflict over creating unnecessary monopolies and excessive profits.
openaire +1 more source
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Ca-A Cancer Journal for Clinicians, 2022Paolo Tarantino +2 more
exaly